🚀 Exciting News from CUTISS! 🚀 We're delighted to announce the first closing of CHF 25 million in our Series C funding round! This funding supports the continued development and path to commercialization of our skin cell therapies denovoSkin™ and Viticell®. A huge thank you to the new US-based co-lead investor and the other Swiss and international investors. This milestone allows us to advance to Phase 3 clinical trials and move closer to bringing our life-changing therapies to patients. We invite additional investors to join us on our mission to transform skin surgery and improve patient outcomes worldwide. For more details, read our press release: https://lnkd.in/eUVecez2 #RegenerativeMedicine #Biotech #Innovation #FundingNews #SeriesC
Best of luck!
Congratulations Daniela & the Cutiss Team 👏
Großartig 👏
Congratulations 🎉
Well done!
Congratulations, Daniela!!
Congrats Daniela Marino & team!
Congrats Daniela! Ad maiora!
Head of development - Fondation Sophia Antipolis
5mobravo